Biomarkers and surrogate end points in clinical trials of tuberculosis treatment - Reply to Davies et al.

被引：0

作者：

Walzl, Gerhard

Mistry, Rohit

Dockrell, Hazel M.

van Helden, Paul D.

Cliff, Jacqueline M.

机构：

[1] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England

[2] Univ Stellenbosch, Fac Hlth Sci, Dept Med Biochem, ZA-7505 Tygerberg, South Africa

来源：

JOURNAL OF INFECTIOUS DISEASES | 2007年 / 196卷 / 04期

关键词：

D O I：

10.1086/519746

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：649 / 650

页数：2

共 50 条

[31] Some statistical issues in the design of cancer clinical trials with surrogate end points
Piantadosi, S
ARCHIVES OF NEUROLOGY, 2000, 57 (08) : 1233 - 1233
[32] Blood in the stomach as a surrogate for clinical end points in GI bleeding trials.
Hawkey, GM
Stack, WA
Cole, AT
Long, RG
Logan, RFA
Hawkey, CJ
GASTROENTEROLOGY, 1998, 114 (04) : A146 - A146
[33] Adequate relief in IBS treatment trials:: Corrections to errors stated by whitehead et al. -: Reply
Whitehead, William E.
Palsson, Olafur S.
Levy, Rona L.
Feld, Andrew D.
VonKorff, Michael
Turner, Marsha
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (12): : 2885 - 2886
[34] Reply to Yew et al., "Vitamin C and Mycobacterium tuberculosis Persisters"
Vilcheze, Catherine
Jacobs, William R., Jr.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (11)
[35] Molecular epidemiology of tuberculosis - Reply to Boyd and Bothamley and to Franzetti et al.
Girardi, E
Sabin, CA
Monforte, AD
CLINICAL INFECTIOUS DISEASES, 2006, 42 (10) : 1499 - 1500
[36] In Assessing Surrogate Clinical Trial End Points: Drug Safety Is a Requisite Reply
McGuire, William P.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) : 1512 - 1512
[37] Reply to Martora et al. "reply to Dalbavancin for the treatment of severe hidradenitis'
Koumaki, Dimitra
Evangelou, Georgios
Koumaki, Vasiliki
Ioannou, Petros
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (01) : E117 - E118
[38] Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency
Maeda, H.
Kurokawa, T.
ANNALS OF ONCOLOGY, 2015, 26 (01) : 211 - 216
[39] The unblinding of statisticians in clinical trials: commentary on Iflaifel et al., Trials 2023
Parker, Richard A.
TRIALS, 2023, 24 (01)
[40] The unblinding of statisticians in clinical trials: commentary on Iflaifel et al., Trials 2023
Richard A. Parker
Trials, 24

← 1 2 3 4 5 →